Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4575 Target Snapshot

Dual specificity tyrosine-phosphorylation-regulated kinase 3 · SINGLE PROTEIN · Homo sapiens

1,241Compounds
227Assays
4Approved Drugs
1,020.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt O43781. Use UniProt O43781 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O43781 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dual specificity tyrosine-phosphorylation-regulated kinase 3 as ChEMBL target CHEMBL4575, mapped to UniProt O43781. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dual specificity tyrosine-phosphorylation-regulated kinase 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4575
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O43781
Dual specificity tyrosine-phosphorylation-regulated kinase 3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Dual specificity tyrosine-phosphorylation-regulated kinase 3 is the right protein anchor across sources, using UniProt O43781 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDual specificity tyrosine-phosphorylation-regulated kinase 3
UniProt AccessionO43781
Component TypeProtein
Sequence Length588 aa

Dual specificity tyrosine-phosphorylation-regulated kinase 3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Dual specificity tyrosine-phosphorylation-regulated kinase 3, mapped to UniProt O43781. Sequence length is 588 aa.

Mapped IDO43781
Review nameDual specificity tyrosine-phosphorylation-regulated kinase 3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

4
Approved
3
Phase III
4
Phase II
5
Phase I
Assay Mix

Activity Type Distribution

IC50487.0
KI533.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4546504 9.98 IC50 0.104 Preclinical
CHEMBL3728543 9.0 IC50 1.0 Preclinical
CHEMBL3728359 9.0 IC50 1.0 Preclinical
CHEMBL5422486 8.7 IC50 2.0 Preclinical
CHEMBL1986943 8.3 Ki 5.012 Preclinical
CHEMBL1974870 8.3 Ki 5.012 Preclinical
CHEMBL2001751 8.1 Ki 7.943 Preclinical
CHEMBL2006439 8.1 Ki 7.943 Preclinical
CHEMBL1997129 8.1 Ki 7.943 Preclinical
CHEMBL3730504 8.0 IC50 10.0 Preclinical
Distribution

pChEMBL Value Distribution

81
5.0
186
5.5
165
6.0
79
6.5
39
7.0
29
7.5
15
8.0
1
8.5
2
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

ABEMACICLIB
CHEMBL3301610
Approved 2017
Assay Landscape

Assay Landscape

227
Total Assays
366
Tested Compounds
2
Assay Types
Binding — 226 assays, 366 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 189 230 6.2
assay format 34 103 6.1
cell-based format 3 33 6.5
Functional — 1 assays, 214 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 214 6.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine